Development of Novel Vaccine Using Hybrid Liposomes for Cancer Therapy
Project/Area Number |
21560813
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Biofunction/Bioprocess
|
Research Institution | Sojo University |
Principal Investigator |
GOTO Koichi 崇城大学, 生物生命学部, 教授 (30279377)
|
Co-Investigator(Kenkyū-buntansha) |
UEOKA Ryuichi 崇城大学, 生物生命学部, 教授 (70099076)
|
Project Period (FY) |
2009 – 2011
|
Project Status |
Completed (Fiscal Year 2011)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
Keywords | 免疫学 / 癌 / リポソーム / ワクチン / T細胞 |
Research Abstract |
The immunotherapeutic effects of hybrid liposomes(HL-MUC-1/mB7-1) composed of phospholipids(DMPC) and nonionic surfactants(Tween 80) including synthetic MUC-1 antigen peptides and recombinant mB7-1 proteins were examined. In vivo experiments, the prolonged survival was observed in mouse models with breast cancer cells after the treatment of HL-MUC1/mB7-1.The results suggested that HL-MUC1/mB7-1 could have the possibility of novel liposome vaccine for cancer therapy.
|
Report
(4 results)
Research Products
(33 results)